# OnCo record all-ph-like (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/all-ph-like/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "all-ph-like" ;
  schema:name "Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)"@en ;
  schema:alternateName "Ph-like ALL"@en, "BCR::ABL1-like ALL"@en, "B-ALL with BCR::ABL1-like features"@en ;
  schema:description "Ph-like leukaemia behaves like Philadelphia chromosome-positive leukaemia, with the same kind of overactive growth signalling, but lacks the BCR::ABL1 gene itself. It is caused by a scattered set of gene fusions and mutations, many of them blockable by existing kinase pills such as dasatinib or ruxolitinib, and it is now screened for at diagnosis so those drugs can be tried."@en ;
  schema:url <https://onco.cc/cancers/all-ph-like/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia> ;
  schema:citation <https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia>, <https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq> ;
  onco:tag "subtype-page", "paediatric" ;
  onco:related <https://onco.cc/cancers/all-paediatric-ph-positive/>, <https://onco.cc/cancers/all-paediatric-high-risk/>, <https://onco.cc/cancers/aya-cancers/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/flow-cytometry-mrd/> ;
  onco:targets <https://onco.cc/targets/jak2/>, <https://onco.cc/targets/epor/>, <https://onco.cc/targets/pdgfrb/>, <https://onco.cc/targets/bcr-abl/>, <https://onco.cc/targets/cd19/> ;
  onco:institutions <https://onco.cc/institutions/childrens-oncology-group/>, <https://onco.cc/institutions/st-jude/> ;
  onco:terms <https://onco.cc/terms/philadelphia-chromosome/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ph-like-all/>, <https://onco.cc/terms/b-all-cytogenetic-risk/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-hunger-mullighan-all-children-nejm-2015/>, <https://onco.cc/key-papers/paper-roberts-ph-like-all-nejm-2014/>, <https://onco.cc/key-papers/paper-den-boer-bcr-abl1-like-all-lancet-oncol-2009/>, <https://onco.cc/key-papers/paper-mullighan-ikzf1-nejm-2009/> ;
  onco:pipeline <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/technologies/cgp/> ;
  onco:standardOfCare <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/targets/pdgfrb/>, <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/targets/jak2/>, <https://onco.cc/targets/epor/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/technologies/allogeneic-hsct/> .